In Model IV, human insulin users without use of ACEI/ARB or with a short-term use of ACEI/ARB for <2 years had a significantly lower risk of breast cancer, while those who had been treated with ACEI/ARB for a longer term (≥2 years) showed a neutral risk association. This evidence concerns the gene INS and breast cancer.